Other News

Endologix Appoints John Onopchenko as Chief Executive Officer

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John Onopchenko as the Company’s Chief Executive Officer, effective immediately. Dan Lemaitre, Chairman of the Board of Directors of Endologix, Inc., commented, “We are very pleased to welcome […]

BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance

FRANKLIN LAKES, N.J., May 3, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018.  This represents an increase of 42.2 percent from the prior-year period, which is primarily due to the acquisition […]

Cardiac Insight, Inc. to Showcase Industry-First Cardiac Devices for Atrial Fibrillation and Sudden Cardiac Arrest Risk Detection at Heart Rhythm 2018, Heart Rhythm Society’s 39th Annual Scientific Sessions, May 9-11, Exhibit 1071

KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a leading U.S. developer of wearable cardiac medical devices and diagnostic software systems with proprietary algorithms, announced today the company will showcase its innovative solutions for the first time at Heart Rhythm Society’s 39th Annual Scientific Sessions. Heart Rhythm 2018 will be held May 9-11, 2018 […]

Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy (NCT03458130). The Phase 2 trial will enroll […]

Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior Year

DANVERS, Mass., May 03, 2018 — ABIOMED, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported fourth quarter fiscal 2018 revenue of $174.4 million, an increase of 40% compared to revenue of $124.7 million for the same period of fiscal 2017.  For fiscal year 2018, total revenue […]

Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter

ABBOTT PARK, Ill., May 3, 2018 /PRNewswire/ — Abbott  (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analyzing data in a novel manner to create […]

Intact Vascular Announces Enrollment Completion of the Tack Optimized Balloon Angioplasty III (TOBA III) Clinical Trial

WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized Balloon Angioplasty III (TOBA III) clinical trial has completed enrollment. A total of 200 patients have been enrolled in TOBA III at 14 sites in Europe. The TOBA III study is a […]

HeartSciences Announces Professor Peter Macfarlane Joins Clinical Advisory Board

SOUTHLAKE, Texas–(BUSINESS WIRE)–HeartSciences, a U.S.-based medical device company that is leading innovation in the field of electrocardiology through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence, announced today that Peter W. Macfarlane has joined its board of clinical advisors. Professor Peter W. Macfarlane, DSc eFESC FRSE, […]

LivaNova Reports First Quarter 2018 Results

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2018. For the first quarter of 2018, worldwide sales from continuing operations were $250.4 million, an increase of 10.4 percent on a reported basis and an increase […]